SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced NSCLC. Br J Cancer. 1995; 71: 366370.
  • 2
    Modi S, Katherine SP, Duck ET, et al. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol. 2002; 20: 36653673.
  • 3
    Ramirez AJ, Towlson KE, Leaning MS, et al. Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer. 1998; 78: 14881494.
  • 4
    Langendijk JA, Aaronson NK, de Jong JM, et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2001; 19: 21232133.
  • 5
    Tester WJ, Jin PY, Reardon DH, et al. Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer. 1997; 79: 724729.
  • 6
    Langendijk JA, ten Velde GP, Aaronson NK, et al. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000; 47: 149155.
  • 7
    Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus GCSF. J Natl Cancer Inst. 1995; 87: 13161322.
  • 8
    Osoba D, Brada M, Yung WK, et al. Health-related QoL in patients treated with temozolomide vs. procarbazine of recurrent gliobalstoma multiforme. J Clin Oncol. 2000; 18: 14811491.
  • 9
    Maher EJ, Hopwood P, Girling DJ, et al. Measurement of outcome in palliative oncology. J Cancer Care. 1994; 3: 94102.
  • 10
    Cella D, Eton DT, Fairclough DL, et al. What is clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperation Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002; 55: 285295.
  • 11
    Lokich J. Tumor response and survival end points in clinical trials: a clinician's perspective. Am J Clin Oncol. 2004; 27: 494496.
  • 12
    Bernhard J, Thurlimann B, Hsu Schmitz SF, et al. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine therapy: does quality of life matter? J Clin Oncol. 1999; 17: 16721679.
  • 13
    Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000; 18: 23952405.
  • 14
    Ramirez AJ, Towlson KE, Leaning MS, et al. Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer. 1998; 78: 14881494.
  • 15
    Glass GV. Primary, secondary and meta-analysis of research. Educ Res. 1976; 5: 38.
  • 16
    CooperH, HedgesLV, editors. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
  • 17
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 18
    Kenny DA. Meta-analysis: easy to answer. Version II. Storrs, CT: University of Connecticut, 1999.
  • 19
    Shadish WR, Haddock CK. Combining estimates of effect size. In: CooperHM, HedgesLV, editors. The handbook of research synthesis. New York: Russell Sage Foundation, 1994: 261281.
  • 20
    Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando, FL: Academic Press, 1985.
  • 21
    Rosenthal R. The ‘file drawer problem’ and tolerance for null results. Psychol Bull. 1979; 86: 638641.
  • 22
    Persaud R. Misleading meta-analysis. BMJ. 1996; 312: 125.
  • 23
    Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985; 3: 827841.
  • 24
    Kelly K. The benefits of achieving stable disease in advanced lung cancer. Oncology. 2003; 17: 957963.
  • 25
    Mazumdar M, Smith A, Schwartz LH, et al. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004; 57: 358365.
  • 26
    Popov I, Jelic S, Radosavljevic D, et al. The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is “stable disease” a homogenous response category? Neoplasma. 1999; 46: 132139.
  • 27
    Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999; 17: 2530.
  • 28
    Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic NSCLC: a phase I-II study. J Clin Oncol. 1999; 17: 23162325.
  • 29
    Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and QoL data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002; 20: 45744580.
  • 30
    Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999; 17: 32703275.
  • 31
    Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine, and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998; 9: 2692731.
  • 32
    Osoba D, Brada M, Yung WK, et al. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000; 36: 17881795.
  • 33
    Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18: 39123917.
  • 34
    Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999; 17: 27622771.